ViaCyte Overview

  • Founded
  • 1999
Founded
  • Status
  • Private
  • Employees
  • 95
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 28

ViaCyte General Information

Description

Operator of a regenerative medicine company intended to discover, develop and commercialize novel cell replacement therapies to treat human diseases. The company's therapies are based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in a retrievable and immune-protective encapsulation medical device, enabling healthcare institutions to reduce diabetes-related complications efficiently.

Contact Information

Website
Formerly Known As
Novocell, CyThera
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 3550 General Atomics Court
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

ViaCyte Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ViaCyte Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
24. Secondary Transaction - Private 00000 Completed Clinical Trials - General
23. Later Stage VC (Series D) 26-May-2020 0000 00000 00000 Completed Clinical Trials - General
22. Corporate 25-Sep-2018 0000 00000 Completed Clinical Trials - General
21. Grant 17-Apr-2018 00.00 00000 Completed Clinical Trials - General
20. Grant 15-Dec-2017 00.00 00000 Completed Clinical Trials - General
19. Later Stage VC 22-May-2017 0000 00000 Completed Clinical Trials - General
18. Grant 01-Jan-2017 000.00 00000 Completed Clinical Trials - General
17. Grant 11-Sep-2014 000.00 00000 Completed Clinical Trials - General
16. Later Stage VC (Series C1) 17-Jul-2013 $16.5M $104M Completed Clinical Trials - General
15. Grant 26-Oct-2012 $10.1M $87.1M Completed Clinical Trials - General
To view ViaCyte’s complete valuation and funding history, request access »

ViaCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D2 000,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series D1 000,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series D-IA 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C1 00,000,000 00.000000 00 00 00 00 00 0.000
Series C 00,000,000 00.000000 00 00 00 00 00 0.000
Series B 27,876,992 $0.001000 8% $1 $1 1x $1 3.93%
Series A 8,020,005 $0.001000 8% $1 $1 1x $1 1.13%
To view ViaCyte’s complete cap table history, request access »

ViaCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a regenerative medicine company intended to discover, develop and commercialize novel cell replacement thera
Drug Discovery
San Diego, CA
95 As of 2020
00000
000000 - 000 00000

00000 00

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqu
0000 000000000
Cambridge, MA
00000
0000 0000-00-00
000000&0 00000

00000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat no
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ViaCyte Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Semma Therapeutics Formerly VC-backed Cambridge, MA 00000 000000&0 00000
00000000 Venture Capital-Backed South San Francisco, CA 00 00000 0000000000 00000
000000 000000000 Formerly PE-Backed Germantown, MD 0 000.00 000000&0 000.00
000000000 Formerly VC-backed Tucson, AZ 00 000.00 000000&0 000.00
0000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

ViaCyte Executive Team (15)

Name Title Board Seat Contact Info
Brittany Bradrick Chief Financial Officer
Steve White Chief Technology Officer
Kevin D'Amour Ph.D Chief Scientific Officer and Vice President of Research
Anne Sandan Vice President of Finance and Corporate Controller
Liz Bui JD Vice President, Intellectual Property Counsel & Diversity & Inclusion Officer
You’re viewing 5 of 15 executive team members. Get the full list »

ViaCyte Board Members (14)

Name Representing Role Since
Adam Koppel MD Bain Capital Board Member 000 0000
Asish Xavier Ph.D Self Board Member 000 0000
Fred Middleton Sanderling Ventures Board Member 000 0000
Heath Lukatch Ph.D TPG Biotech Board Member 000 0000
Ian Smith Self Executive Chairman 000 0000
You’re viewing 5 of 14 board members. Get the full list »

ViaCyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ViaCyte Investors (28)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Bain Capital PE/Buyout Minority 000 0000 000000 0
RA Capital Management Venture Capital Minority 000 0000 000000 0
TPG Biotech Venture Capital Minority 000 0000 000000 0
CRISPR Therapeutics Corporation Minority 000 0000 000000 0
The National Institute of Diabetes and Digestive and Kidney Diseases Government 000 0000 000000 0
You’re viewing 5 of 28 investors. Get the full list »

ViaCyte Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 (000000000 18-Dec-2015 000000000000000000 Biotechnology 0000 0000000 00.0
To view ViaCyte’s complete acquisitions history, request access »